US-based medical device maker Ivenix closed a $42m series D round led by healthcare research and development services company WuXi PharmaTech’s corporate venturing unit, WuXi Healthcare Ventures, on Tuesday.
The round also featured venture capital partnership Cardinal Partners, asset manager Cica, investment firm Easterly Capital, VC firm SCP Vitalife Partners and Fidelity Biosciences, a division of financial services firm Fidelity Investments, all of which participated as existing investors.
Founded in 2007, Ivenix has developed a device (pictured) that facilitates drug…
